Xiao-kun Zhang

Biography

Xiao-Kun Zhang is a Senior Scientific Advisor of Aranda Pharma Ltd. Xiao-Kun is internationally recognized nuclear hormone receptor scientist with over 120 peer-reviewed scientific publications, 9 US and 7 Chinese patents. He is among the first group of recipients of the China 1000 talent program. His groundbreaking research has led to discovery of novel target pathways for anticancer therapeutics and subsequent development of Targretin, approved by the FDA for the treatment of Cutaneous T-Cell Lymphoma, and TX803 currently developed for colorectal cancer by Tarrex Biopharma Ltd. Xiao-Kun received his PhD degree in Biochemistry from the University of Vermont, USA. He is a co-founder and Chief Scientific Advisor of Tarrex Biopharma Ltd, China. He currently holds positions of the Dean of School of Pharmaceutical Sciences at the Xiamen University, China and Professor of the Sanford-Burnham Medical Research Institute, California USA.

Research Interest

Pharmaceutical Sciences